Aspen Pharmacare Holdings Limited APN
JSE · South Africa · Health Technology
ZAc 15,873.00+39.00 (+0.25%)
Market open· · ZAc · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · ZAc · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Here is how Aspen Pharmacare (APNHY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Here is how Aspen Pharmacare (APNHY) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
Aspen Pharmacare Holdings Ltd (APNHF) guides to over 50% NHEPS growth in FY27, driven by a raised sterile EBITDA target and a strong net cash position.
Aspen Pharmacare Canada Inc., a subsidiary of Aspen Pharmacare Holdings Limited ("Aspen"), today announced that Health Canada has approved ᴾʳAspen-Semaglutide, a generic equivalent of Ozempic® (semaglutide injection), for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.¹ Aspen-Semaglutide will offer both the 2 mg and 4 mg pen formats.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.